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SUMMARY 
A wide range of experimental tumour models, each with distinct advantages and disadvantages, is nowadays available. 
Due to the inherent differences in their complexity and functionality, the choice of the model is usually dependent on 
the application. Thus, to advance specific knowledge, one has to choose and use appropriate models, which complexity 
is largely dependent on the hypotheses to test, that is on the objectives. Whatever the model chosen, the complexity 
of cancer is such that none of them will be able to fully represent it. In vitro tumour models have provided important 
tools for cancer research and still serve as low-cost screening platforms for drugs. The improved understanding of cancer 
as “organ system” has pushed for increased accuracy and physiological relevance of in vitro tumour models that have 
in parallel increased in complexity, diversifying their output parameters as they progressed in view to recapitulate the 
most critical aspects such as the dimensionality of cell cultures (2D versus 3D), the mechanical stimuli, the multicellular 
interactions, the immune interactions and the soluble signalling. 
Animal models represent the in vivo counterpart to cell lines and are commonly used for studies during the preclinical 
investigation of cancer therapy to determine the efficacy and safety of novel drugs. They are superior to in vitro models 
in terms of physiological relevance offering imitation of parental tumours and a heterogeneous microenvironment 
as part of an interacting complex biochemical system. In the present review we describe advantages and limits of 
major preclinical models used in Oncological Pharmacology.
Impact statement
Integration of in vitro, in vivo and in silico cancer tumor 
models is vital to obtain relevant data predictive for efficacy 
and toxicity in Oncological Pharmacology.
Key words
Oncology; cell lines; 3D models; engineered mouse 
models; zebrafish models; immunocompromised mouse 
models.
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INTRODUCTION 
The past decades witnessed a significant ad-
vancement of the knowledge of the molecu-
lar bases of carcinogenesis and mechanisms 
of cancer growth, and unveiled the determin-
ing role of the immune system in these pro-
cesses. However, despite scientific advances 
in the understanding of cancer biology, nov-
el anti-cancer drugs are struggling to emerge 
and the success rate of oncology drug devel-
opment is the lowest among all therapeutic 
areas (1). Preclinical studies using mice have 
been extensively used to study the aetiology 
and pathophysiology of human cancers,  and 
are essential for anticancer drug development. 
However, due to their poor predictive value, 
only approximately 5% of anticancer drugs 
are approved for the market, even if preclin-
ical studies are successful (2-4), major reason 
behind this low success rate is the poor pre-
diction of clinical efficacy and toxicity profiles 
from animal and in vitro experiments. This is 
related to the extreme complexity of tumours 
that are not just a heap of cells that prolifer-
ate without control (5). Cancer formation and 
progression are complex multistep processes 
involving genetic, epigenetic, and metabolic 
alterations. In tumour masses heterogeneous 
cancer cells reside in complex microenviron-
ments in which they are intertwined with other 
cell types – among which endothelial, hema-
topoietic, stromal and immune cells – extracel-
lular matrix components (ECM), and subjected 
to a variety of physical and chemical stimuli 
that drive cell behaviour towards transforma-
tion and malignancy (6-8). Interactions within 
the tumour microenvironment (TME) also help 
create metabolic changes, such as hypoxic en-
vironment and nutrient gradients, which fur-
ther contribute to the heterogeneity of can-
cer cells. This view has increased the ability to 
identify crucial features of the cancer cells and 
provided more cues for the identification of 
relevant drug targets. However, the complex-
ity often hinders the ability to detail relation-
ships, and an in-depth understanding of this 
intricate interplay is limited by current model 
systems, which fail to substantiate findings and 
to elicit sufficient reproducibility.
It is important to understand that each type 
of cancer model possesses inherent advan-
tages and limitations (9). Different animal and 
human cancer models should be used at the 
various stages of the drug discovery process 
according to the features of the new therapeu-
tic agent under investigation. Using a variety 
of pre-clinical models can better mirror the hu-
man cancer heterogeneity and define the drug 
doses and schedules to be investigated in clin-
ical trials (10, 11).
In this review, the advantages and limits of the 
main preclinical oncology models are reported 
focusing on two-dimensional (2D) and 3D cel-
lular models, immunocompromised and immu-
nocompetent mouse models, zebrafish mod-
els and integrated mathemathical approaches. 
IN VITRO MODELS
The goal of in vitro research in cancer phar-
macology is to develop a model that can sim-
ulate the drug response of a tumor before ad-
ministering it to animals and patients. There 
are different in vitro models that can be used: 
computational models, in silico models, animal 
and human cell models and three-dimensional 
(3D) models. Not necessarily, in testing a drug 
to verify its efficacy in oncology, it is necessary 
to use all the mentioned models but it would 
be advisable to be able to exploit more than 
one model before moving on to in vivo experi-
mentation. In fact, the fostering and extending 
of the in vitro approaches meet the directives 
of European legislation on the use of animal 
models in experimentation since well match 
the replacement, reduction and refinement of 
the 3R principle. 
2D culture models
Two-dimensional (2D) cell cultures represent 
a simple and widely used experimental mod-
el in research. However, they have limitations, 
such as the inability to reconstruct the correct 
three-dimensional organization and the com-
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plexity of the tumor microenvironment (TME) 
of human tissue. To date, the in vitro model 
systems are not sufficently predictive, because 
they do not take into account tumor complex-
ity and heterogeneity and do not reproduce 
the complex cellular and microenvironmental 
networks that are crucially involved in the initi-
ation, persistence, invasion and recurrence of 
the tumor (11, 12). 
Though in vitro 2D models are considered as 
“simple” relative to 3D and in vivo models, all 
existing drug approved began their journey 
to the clinic targeting classical 2D adherent 
cell culture models in the laboratory. Although 
exceptions exist, drugs that have little effect 
on the viability of cancer cells grown in these 
conditions often do not have efficacy in more 
realistic 3D in vitro and in vivo models. There-
fore, this approach has great utility in initial 
high-throughput screens to identify potential 
hits worth additional investigation. Conven-
tional 2D culture allows for a variety of phe-
notypes and striking features of cancers to be 
interrogated, including cytotoxicity, prolifera-
tion, mobility, invasiveness, adaptability to hy-
poxic microenvironments, protein expression 
and pathway plasticity, drug sensitivity stud-
ies, drug durability, molecular characterization, 
and genomic/genetic characterization. 
Of additional benefit, monocultures are free 
from contaminating cells, which allows for a 
clear understanding of what is occurring spe-
cifically within cancers cells relative to other 
cell types in the TME in response to a given 
insult, which can be accomplished through 
co-culture using transwell plates. 
Tumor immortalized cell lines
Tumor immortalized cell lines were established 
over 30 years ago and are still commonly used 
as in vitro model for drug screening (13-15). 
Since then, a huge variety of animal or human 
cancer cell lines is available in bioresource cen-
ters, such as the ATCC (American Type Culture 
Collection) (16). Such established cell lines, 
associated with simple and low-cost mainte-
nance, have been widely useful for elucidating 
the progressive events leading to malignancy 
and the mechanisms of tumor cellular physiol-
ogy (17). Recently, Nusinow et al. (2020) have 
screened the cell lines in the Cancer Cell Line 
Encyclopedia (CCLE) through quantitative pro-
filing of thousands of proteins, hence these 
data represent a new robust resource to ex-
plore cellular behavior and facilitate cancer re-
search (18). 
Although meaningful insights can be gained 
from 2D culture, drawbacks to this approach 
include lack of heterogeneity and the existence 
of phenotypes that are observed on plastic that 
do not reflect cancer behavior in vivo, and vice 
versa. For example, melanoma cells proliferate 
much more rapidly in vitro than in vivo, likely 
due to high serum concentrations and stiffness 
of support (i.e., plastic) (19). Genetic drift also 
occurs in long-term passaged cells which can 
lead to the high variability and reduced repro-
ducibility of the results, due to adaptations to 
the non-physiological conditions (i.e., oxygen 
and nutrient levels) in 2D cell culture. 
Human cancer-derived cell lines are a simple 
and quick resource and an important model 
for in vitro cancer research. Thanks to these 
models it has been possible to understand 
much of the biology of the neoplastic cell and 
they have been crucial for the screening of 
antineoplastic drugs and to identify potential 
new treatments. Although, encouraging results 
have been obtained, for example from a study 
using sequencing data and microarray expres-
sion profiles from 947 human cancer cell lines, 
coupled with drug responses for 24 anticancer 
drugs across 479 cell lines. The study under-
lined that the cell lines “may provide repre-
sentative genetic proxies for primary tumors 
in many cancer types” (17). So, not all cancer 
cell lines have the same value as tumor mod-
els. Another important problem to take into 
consideration, that could represent a criticality 
in the use of cell cultures as an experimental 
model, is the incorrect identification of the cell 
line. An important step to bypass this prob-
lem was to create publicly searchable data-
bases through standardized protocols for the 
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authentication of human cell lines using short 
tandem repeat profiling (20). In the first de-
cade of the 2000s, the advent of omic technol-
ogies allowed the characterization of tumors 
at the molecular level which, in addition to 
revealing the great genetic heterogeneity of 
tumors, changed the focus from convention-
al chemotherapeutic agents towards targeted 
therapy. The specific modification of the gene 
structure of cells in culture, through the inser-
tion of missing genes or the selective block of 
overexpressed genes, gives us the possibility 
to mimic in the laboratory what happens in a 
specific tumor. Today, different strategies are 
widely used to study the morphological and 
functional effects associated with the activity 
of single genes: it is possible to generate cell 
lines that can produce substantially any type of 
gene product through transfection and/or in-
fection techniques with suitable vectors (plas-
mid or retrovirus). Furthermore, specific meth-
ods of gene suppression (antisense RNA, small 
interfering RNA) allow to easily and selective-
ly inhibit the activity of single genes. To study 
the complex mechanisms to be put in place to 
bypass multi-drug resistance, it is possible to 
create in vitro models of resistance to conven-
tional and target antitumor drugs and to use 
human immortalized cancer cell lines derived 
from cancer patients showing primary resis-
tance. However, the identification of promis-
ing molecules must be subsequently validated 
in other experimental models, for example, on 
primary cultures of similar or different deriva-
tion compared to the cells initially used in the 
screening program. 
The number of passages a cell line undergoes 
can lead to such extensive modifications in its 
characteristics that no longer reflect the tumor 
from which it was derived, as in the case of an-
euploidy. Cell lines no longer retain the tumor 
heterogeneity present in primary cancer and 
do not contain the relevant components of the 
TME. One of the most relevant advantages in 
pharmacology is the use of cell cultures to 
study the effects of molecules on human cells, 
exposing the cells directly to the substances 
to be tested at different concentrations, hav-
ing reproducible results in a short time. Fur-
thermore, the loss of components involved in 
homeostatic regulation in vivo also occurs.
Primary cell culture
Primary cultures are made up of cells that arise 
from a tissue or organ, extracted from both 
animal or human explant. These cells are able 
to duplicate only for a limited number of pas-
sages, then undergo senescence regardless of 
the presence of metabolites appropriate for 
growth. However they represent an excellent 
study model as they retain most of the in vivo 
cell characteristics. In the oncology field, for this 
reason, primary cultures are the closest model 
to in vivo, but they are also more delicate for 
the growing conditions that require (21).
Others
Finally, through immunohistochemical tech-
niques on paraffinized tissues but also molecu-
lar characterization on fresh tumor tissues, it is 
also possible to identify and correlate the his-
togenetic classification of tumors to determine 
the site of origin of metastatic tumors and to 
identify molecules with prognostic and/or ther-
apeutic significance, identify the patients who 
can benefit from specific treatments (e.g., mo-
lecularly targeted “targeted therapy”, immu-
notherapy) and monitor the response to these 
therapies and the onset of possible resistance.
3D cell culture models
The newly developed 3D in vitro culture meth-
ods are more tightly to in vivo condition. One 
of the first 3D cultures of human tumor stem 
cells was carried out in soft agar by Hamburg 
and Salmon in the 1970s (22). Since then, 
several different types of 3D models, such as 
spheroids (23) and organoids (24), have been 
developed and extensively improved to simu-
late a plethora of diseases, including cancer. 
Firstly, non-scaffold-based 3D cultures were 
derived from established monolayer cell lines 
and were named spheroids. Such spherical ag-
gregates of malignant cells, i.e. multicellular 
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tumor spheroids, were used as in vitro mod-
els of tumor microregions and avascular stage 
of tumor growth (25). Spheroids reproduce the 
main features of solid tumours such as 3D ar-
chitecture, cellular heterogeneity, cell-cell sig-
nalling, extracellular matrix deposition, growth 
kinetics, gene expression patterns and drug 
resistance mechanisms (26). 
More recently, organoid technology has re-
vealed a great potential in opening up new 
opportunities for the development of novel 
therapies in cancer research (27-29). The first 
organoid model was established by using in-
testinal stem cells that express single leu-
cine-rich repeat-containing G protein-coupled 
receptors 5 (LGR5) (30). Sato et al. demonstrat-
ed that intestinal crypt-villus units are self-orga-
nizing structures, which are built from a single 
stem cell (30). Unlike spheroids, organoids can 
be expanded long term and exhibit a more 
advanced and organized architecture that re-
capitulate the genetic and structural features 
of the native organ, hence the name “mini-or-
gans” (30, 31). It is worthy to note that organ-
oids can be cryopreserved and remain geneti-
cally and phenotypically stable.
Stem cells or multipotent progenitor cells de-
rived from human biopsies were expanded 
in vitro to obtain stem cell-derived organoid 
models and have allowed to develop highly 
reproducible and long-lived organoids from 
single cells (30, 32, 33). As such, organoids 
can be generated from adult stem cells (ASCs) 
(34), embryonic stem cells (ESCs) (35), and 
induced pluripotent stem cells (iPSCs) (36). 
However, the efficiency of stem cell-based tu-
mor organoids from patients may depend on 
the cancer type and the presence or absence 
of specific oncogenic alterations, potentially 
choosing for the outgrowth of tumour sub-
clones and loss of the genetic heterogeneity 
of the tumour it is derived from (38). There-
fore, it appears more helpful to develop tu-
mour organoids directly from tumors than to 
use stem cells. Actually, organoids can be di-
rectly generated from the patient tumour tis-
sue following surgery or endoscopic biopsy to 
obtain patient-derived organoids (PDOs) (see 
for review 39). 
PDOs, defined as multicellular extracellular 
matrix (ECM)-dependent units, recapitulate 
accurately histopathologic and genomic pro-
files of the tissue of origin while maintaining 
genomic stability throughout passaging (27, 
40). Huge pools of PDOs are generated and 
biobanked, offering new possibilities as pow-
erful preclinical models able to account for 
interpatient variability (29, 39). Indeed, pa-
tients’ tumors have genetic and epigenetics 
changes that promote cancer growth and 
spread, thus their response to the treatment 
is significantly different. 
So far, organoid technology is revolutionizing 
many areas of science, including cancer re-
search and precision medicine. However, one 
of the intrinsic limitations of organoid culture is 
the lack of stroma, blood vessels and immune 
cells (11). As cancer immunotherapy is holding 
a pivotal role in the clinic, researchers have re-
cently shown that epithelial organoid cultures 
can be used in co-culture conditions or may 
also be integrated into organ-on-a-chip plat-
forms, allowing the build-up of more complex 
culture systems (41-44).
Table I summarizes the main advantages and 
disadvantages of all described in vitro models.
IN VIVO MODELS
Immunocompetent mouse and 
rat models: syngeneic, genetically 
engineered mouse and carcinogen-
induced models
Ectopic and orthotopic syngeneic models
Immunocompetent syngeneic models are char-
acterized by the inoculation of cancer-derived 
cell lines or by the implant of cancer tissues 
into genetically identical hosts, namely synge-
neic mice or rats, at the same (orthotopic) or 
different (ectopic) anatomic cancer site. Syn-
geneic ectopic models (SEMs) are useful for 
the in vivo screening of new chemical entities 
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(NCEs) allowing a reproducible and quantita-
tive evaluation of their overall tolerability, an-
ticancer efficacy and pharmacokinetics (PK)/
pharmacodynamics (PD) relationships. Howev-
er, SEMs own restricted clinical predictability 
due to the loss of cancer cells and tumor-asso-
ciated stromal cells heterogeneity and incom-
plete genotypic and phenotypic similarities to 
human cancers (45, 46). 
On the other hands, syngeneic orthotopic 
models (SOMs) better mirror the complex cell-
cell interactions of the primary TME resulting 
in more reliable phenotypic and metastatic 
profiles. Due to their whole immune system, 
SOMs are crucial for evaluating the impact of 
new therapeutic agents on cancer local and 
metastatic invasiveness and occurrence of stro-
mal-related cancer resistance (47). However, as 
SEMs, SOMs do not reflect the heterogene-
ity of tumour cells. Therefore, it is crucial to 
define which genetic profile each model most 
closely depicts to strengthen the response 
predictivity to the various therapeutic agents 
(48). Moreover, SOMs being technically more 
challenging compared to SEMs with highly 
variable rates of cancer take and development 
times are not suitable for the initial evaluation 
of NCEs in widespread screening. Differently 
from sc or ip SEMs in which cancer growth can 
be easily evaluated quantitatively by electron-
ic calipers, in SOMs imaging techniques (e.g., 
bioluminescent imaging, magnetic resonance 
imaging, positron emission tomography and 
ultrasonography) have to be used. 




• simple and low-cost maintenance;
• long term culture;
• amenable to genetic manipulation;
• mainly valuable for drug screening 
and gene expression patterns.
do not reproduce:
– the complex cellular;
– the microenvironmental networks of 
tumor.
2D primary cells • simple and low-cost maintenance;
• mainly valuable for drug screening 
and gene expression patterns;
• may be collected from transgenic mice.
• limited culture period, 
• do not reproduce:
– the complex cellular; 
– the microenvironmental networks of 
tumor.
Spheroids • reproduce 3D architecture,
• cell-cell signalling;
• polarized cell-matrix interactions;
• growth kinetic;
• gene expression patterns; mainly valuable 
for drug resistance mechanism.
• limited culture period; 
• low capability to reproduce the tumor 
histopathologic and genomic profile; 




• well-established culture protocols 
for many tissues;
• long-term culture with progressive 
differentiation;
• can be cryopreserved and remain 
genetically and phenotypically stable;
• amenable to genetic manipulation.
• expensive culture method;
• may lose the genetic heterogeneity of 
the tumour it is derived from; 




• capture interpatient genetic 
heterogeneity;
• recapitulate accurately histopathologic 
and genomic profiles of the tissue  
of origin while maintaining genomic 
stability throughout passaging;
• mainly valuable for precision medicine.
• expensive culture method; 
• access to tissue may be difficult or 
limited; 
• do not model tumour immune 
involvement (amenable to organoid-
immune cell co-culture systems).
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Genetically engineered mouse models
Immunocompetent genetic engineered mouse 
models (GEMMs) are characterized by the 
generation of cancer genetic abnormalities 
that can be modulated in a systemic or in a 
spatial-temporal (conditional) manner. Allow-
ing the study of the pharmacological modu-
lation of specific mutations, these engineered 
models are closer both at genotypic and phe-
notypic levels to human cancers (49). In these 
non conditional models, autochthonous can-
cers develop spontaneously and in the appro-
priate microenvironment in mice. Therefore, 
the effects of NCEs on immune response, 
and local and systemic metastatic spread can 
be efficiently studied with a significant pre-
dictive relevance. However, most of GEMMs 
are characterized by an asynchronous cancer 
development resulting in variability in can-
cer occurrence, frequency and growth. Fur-
ther, GEMMS are obtained in out-bred murine 
strains whose genetic backgrounds may be 
nonuniform influencing the pharmacokinetic, 
the efficacy and safety profiles of anticancer 
agents. These limitations can be overcome 
by conditional GEMMs that allow the specific 
control of gene expression at both time and 
tissue level (50, 51).
On the other hand, GEMMs are highly time 
and cost consuming for assessing statistically 
significant data and generally require imaging 
techniques for monitoring the anticancer effi-
cacy of NCEs under investigation. Gene ed-
iting technologies, such as the CRISPR/Cas9 
system, have significantly reduced the time 
needed to establish a GEM model (52). Gen-
erally, GEMMs are suitable for the later phases 
of the drug discovery process evaluating se-
lected leads that deserve to be investigated in 
specific clinically appropriate GEMMs for sup-
porting the translational process. 
Carcinogen-induced models 
The carcinogen-induced models are among 
the oldest pre-clinical models used (53). These 
autochthonous models are characterized by 
the multistage and time-dependent develop-
ment of solid and hematological cancers in re-
sponse to carcinogens in immunocompetent 
mice and rats. These models are produced in 
out-bred strains of mice and rats characterized 
by different genetic backgrounds and high re-
producible phenotype. Cancer development 
relies on the protocol used and in particular by 
the dose and the schedule of carcinogens. A 
peculiar feature is the similarity of these mod-
els to the multistage progression of human 
cancers (i.e., hyperplasia, dysplasia, pre-ma-
lignant lesion, well differentiated cancer and 
invasive-poorly differentiated cancer). Howev-
er, the carcinogen exposure can be rather se-
vere compared to carcinogen-related human 
cancers (48).
These models are of value in understating the 
stage of cancer development that is more sen-
sitive to the therapeutic agent under investiga-
tion. The models need initial low manipulation 
and costs, but their extended timelines are as-
sociated with safety concerns and increasing 
costs for animal care and maintenance. There-
fore, these models have been replaced by xe-
nograft and GEM models in early stage of drug 
discovery process. To note that these models 
have been pivotal in pointing out and support-
ing the cancer immunoediting theory (54).
Immunocompromised mouse models: 
cell-line derived and patient derived 
xenograft 
The simplest tumour models are the xenograft 
model, in which human cell lines are inoculat-
ed into an immunocompromised mouse and 
tumour growth is monitored with calipers (55).
These preclinical models have been widely 
used, despite their poor predictive validity, as 
they do not reflect the heterogeneity of tumor 
cells nor of TME, particularly when heterotop-
ics (tumor cells injected subcutaneously into 
the flank) rather than orthotopics (tumor cells 
injected into the corresponding anatomical 
position). Moreover, these models do not also 
reflect the multistage process of carcinogene-
sis, as the inoculation is synchronous. There-
fore, it is not expected that pharmacological 
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data derived from one of these tumour mod-
els can predict efficacy in complexity of the 
human disease. Further, limited is their use for 
studying the metastatic process and, conse-
quently, the activity of NCEs on the treatment 
of metastases (56). However, these models 
can be used to investigate the PK, PD and 
toxicity of NCEs, their PK-PD relationship (for 
the optimal dosing regimen selection in clini-
cal trials) and their therapeutic ratio (57).
Patient derived xenograft (PDX) models pro-
vide further confidence for decision-making in 
clinical development and clinical candidate se-
lection (58). In PDX models, resections of hu-
man tumours are implanted into immunosup-
pressed mice (e.g. non-obese diabetic (NOD)/
severe combined immunodeficiency (SCID)). 
PDX models represent the heterogeneity of 
tumour cells and TME (59).The tumors are well 
characterized, both molecularly and histologi-
cally, and can be used in validation target and 
investigation of activity of the new therapeutic 
agents, as well in selection of patients respon-
sive to a new therapeutic agent (58). More-
over, the PDX models, representing a hetero-
geneous patient population (60), can be used 
to perform a preclinical–clinical trial. 
Panels of PDX models have been established 
by academic institutions, research organiza-
tions and pharmaceutical companies, and con-
sortia, such as the European EuroPDX Con-
sortium (http://europdx.eu/news-events.html) 
have been made. Interestingly, in some ret-
rospective studies, the response in PDX mod-
els is predictive of clinical response (61). How-
ever, there are still several limitations to PDX 
models, including the high cost (for using and 
maintaining of the models), the engraftment 
of human tumors into immunodeficient mouse 
strains (which cannot be used for testing immu-
nomodulatory agents) and the use of the het-
erotopic model (subcutaneous tumor injection) 
rather than the orthotopic equivalent (which is 
more technically challenging and associated 
with reduction in engraftment rate) (62).
Recently, in order to use PDX models for the 
development of immunotherapeutic agents, a 
number of humanised PDX models (AVATAR) 
have been generated (63-65). In addition to 
their use in drug discovery, humanised PDX 
models can be used to identify patient-spe-
cific drug response (66) and novel treatment 
strategies for patients non responsive to stan-
dard-of-care treatment options (67). However, 
the limitation are still present. In fact, not all 
tumours are amenable to xenotransplantation, 
the immune response may not be modelled 
and the methodology may not allow transplan-
tation of treatment-resistant cells (68). These 
humanized mouse models also have a limited 
impact on research into metastasis (69-71).
Zebrafish models
In the last decade, the zebrafish (Danio re-
rio) has become an attractive alternative to 
mouse for modeling human cancer diseases. 
The zebrafish possesses unique advantages 
as a versatile tool in cancer research. Zebraf-
ish generates large numbers of progeny, every 
week a pair of adult zebrafish produces sev-
eral hundred fertilized eggs. This aspect of-
fers high confidence in statistical analysis (72, 
73). Furthermore, zebrafish have small sizes 
and require minimal care and husbandry ex-
penses, therefore their maintenance is cheap-
er compared to mice colony and other mam-
mals (73). Interestingly, a direct comparison of 
the zebrafish and human protein-coding genes 
reveals several interesting features: 71.4% of 
human genes have at least one zebrafish or-
thologue and, reciprocally, 69% of zebrafish 
genes have at least one human orthologue. 
Regarding disease, 82% of human morbid 
genes can be related to at least one zebrafish 
orthologue (74). For example, mammals and 
zebrafish share common molecular pathways 
of liver tumor progression (75).
The embryos develop externally and are ini-
tially transparent, whereas the Casper pigmen-
tation mutant zebrafish (roy-/-; nacre-/-), devel-
oped in 2008, remains transparent throughout 
adulthood. The transparency makes embryos 
of zebrafish suitable to direct observe some 
processes through in vivo imaging (76). Be-
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sides, zebrafish genetics is easily manipulated 
allowing us to drive specific homozygosity mu-
tations, producing zebrafish models with ge-
netic defects similar to specific human cancer 
(74). Cancer progression in these animals reca-
pitulates many aspects of the human disease 
allowing the identification of genetic and bio-
chemical features of cancer. Regarding drugs, 
zebrafish efficiently absorbs small molecules 
directly dissolved in water, allowing easy drug 
administration (77). Unfortunately, drug deliv-
ery using immersion therapy is unable to give 
the accuracy of dosing and therefore pharma-
cokinetic studies presents some technical diffi-
culties (78). Nevertheless, a wide range of as-
says can be carried out in the several tumor 
models of zebrafish: compound screening and 
testing, drug reprofiling, target discovery, tar-
get validation and toxicological studies (79). 
Different approaches assessed by the scientif-
ic community, has been developed to induce 
cancer in zebrafish. Each model presents spe-
cific advantages and disadvantages and the 
best way to select the best approach is to 
focus on the aim/question to answer in each 
experimental setting. For instance, cancer in 
adult zebrafish with a completely developed 
immune system and organs, represents a more 
realistic in vivo model compared to embryos, 
which conversely represent a suitable model 
for live imaging techniques.
There are different methods to induce cancer 
in zebrafish, a synopsis is reported below. 
Chemical carcinogenesis was the first ap-
proach used to induce tumor formation in ze-
brafish. Itemized protocols exist that allow the 
development of mutant lines without special 
equipment but simply adding carcinogens to 
the water. Nevertheless, this approach has a 
low rate of tumor formation and the tumor is 
highly heterogeneous for site and type (79).
Genome editing approaches represent meth-
ods able to inactivate or regulate a specific 
gene. The most used techniques to edit the 
genome in zebrafish are TALEs, zinc-finger nu-
cleases, CRISPR/Cas and Morpholino (80-83). 
Currently, many mutant lines are available and 
show a good incidence of tumor formation 
and homogeneity of tumor types. Neverthe-
less, mutant lines are difficult to maintain and 
the study of tumors requires histological anal-
ysis (79). 
Another method is the development of trans-
genic zebrafish models through microinjecting 
of exogenous DNA into embryos. This meth-
od allows the expression of a gene of inter-
est (for example, oncogene or mutant form 
of tumor suppressor) in a particular organ or 
tissue through the use of tissue-specific pro-
moters. The advantages of these approaches 
consist of a high rate of tumor formation, a 
temporal and site control of tumor initiation, 
and, in some cases, the monitoring of tumor 
progression by fluorescence microscopy. The 
main disadvantage is the necessity of high ex-
perience to overcome the difficulties that arise 
during the development of the transgenic ze-
brafish model. 
The last developed approach to generate can-
cer in zebrafish is the transplantation of tumor 
cells. There are: allogeneic transplantation, i.e. 
the transfer of cells from one individual into 
another of the same species, xenotransplanta-
tion, i.e. the implantation of living tumor cells 
from one species to another and orthotopic 
transplantation, i.e. implanting living tumor 
cells from one species to another but into xe-
notransplantation is the transplant into zebraf-
ish embryos of the patient-derived tumor cells 
(zPDX). This approach has relevant translation-
al potentiality in the precision cancer medicine 
area because it represents an efficient and fast 
model to test the patients treatment options 
in an in vivo model having the same molecular, 
genetic, and clinical characteristics of the pa-
tient. Nevertheless, there are also limitations 
in the transplantation. The main is the neces-
sity to perform an experiment before the de-
velopment of the adaptive immune system i.e. 
until 21 days of life, to prevent graft rejection. 
Experiments in adults require immune system 
ablation through radiation or treatment with 
dexamethasone, to avoid engraftment rejec-
tion. Another limitation is the temperature of 
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≤ 35 °C, to which larval xenotransplantation 
experiments are conducted, which is a tem-
perature non-physiological for human cells 
(78). Finally, orthotopic transplantation is not 
always possible due to the absence of a con-
crete organ in zebrafish, such as for breast, 
lung, or prostate.
Table II summarizes the main advantages and 
disadvantages of all described in vivo models.
Integrated mathematical approaches
The complexity of the system we are consid-
ering makes a difficult task to select a unique 
model that embodies all the desired charac-
teristics. A significant link and enrichment of 
in vitro and in vivo systems is provided by in 
silico biological systems, especially integrat-
ed mathematical models (84). In fact, math-
ematical models have the potential to fill in 
gaps of knowledge left by incomplete exper-
imental models of complex “cancer organs”. 
This has prompted the development of many 
mathematical models of cancer, which need 
becomes manifest, as accurate experimental 
models become more difficult to create. The 
broad range of mathematical modelling com-
plexity and techniques gives them almost un-
limited potential in cancer research (85-89). 
Models have been created to examine almost 
any aspect of the complex “cancer system” 
Table II. Advantages and disadvantages of in vivo tumour models used in studies of Oncological Pharmacology.
Model Advantages Disadvantages
Syngeneic models • Useful for the in vivo screening of new 
compounds (safety, efficacy and PK/PD 
relationships);
• time- and cost-effective models for obtaining 
drug translational data; 
• orthotopic models: 
– useful to investigate the metastatic profiles 
of tumors
– useful to investigate immunotherapeutics. 
• Incomplete genotypic  
and phenotypic similarities  
to human cancers;
• do not reflect the heterogeneity  
of tumor cells;
• orthotopic models require imaging 




• Closer both at genotypic and phenotypic 
levels to human cancers; 
• useful to study the pharmacological 
modulation of specific mutations;
• predictive of metastatic potential of tumors;
• useful to investigate immune-therapeutics;
• suitable for the later phases of the drug 
discovery process; 
• useful models for obtaining drug 
translational data.
• Asynchronous cancer development 
• difficult to perform powered 
studies;
• non-conditional models suffer  
of nonuniform genetic 
backgrounds affecting PK,  
efficacy, and safety of drugs;
• highly time and cost consuming  
to perform screening experiments;
• require imaging techniques  




• Similarity to the multistage progression  
of human cancers; 
• useful for tumor-stage sensitivity  
to anticancer drugs;
• low manipulation and costs.
• Severe carcinogen exposure; 
• safety concerns;




• Useful to investigate the PK, PD and toxicity 
of anticancer drugs;
• useful to investigate the PK-PD relationship 
and the therapeutic ratio of anticancer 
drugs.
• Do not reflect the heterogeneity  
of tumor cells;
• do not reflect the tumor 
cell interactions with 
microenvironment; 
• synchronous inoculation. 
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• Reflect heterogeneity of tumour cells  
and tumor microenvironment; 
• tumors are well characterized;
• useful in validation target;
• useful in investigation of activity  
of anticancer drugs;
• useful in selection of patients responsive  
to new anticancer drugs;
• useful to perform a preclinical–clinical trial;
• AVATAR useful for testing 
immunomodulatory agents.
• High cost for maintaining; 
• generally not useful for testing 
immune-modulatory agents; 
• orthotopic models are technically 
challenging;
• many tumors are associated with 
reduction in engraftment rate;
• murine immune response;
• treatment-resistant cells may  
not be transplanted.
Zebrafish • Small size, easy to maintenance 
• large progeny/week; 
• 71.4% of human genes have at least  
one zebrafish orthologue; 
• transparent embryos and adults allow  
in vivo visualization of cancer growth  
and progression (real-time live imaging); 
• zebrafish genetics is easily manipulated; 
• easy drug administration.
• Different diet and environment 
compared to human;
• several mammalian organs  
are not present;
• cold-blooded, the physiology  
is not identic to human;
• immersion therapy is unable  
to give the accuracy of dosing. 
Carcinogen-induced 
tumor in zebrafish
• Simply protocols to add carcinogens  
to the water; 
• easy to set up;
• no need for special equipment or personal 
formation.
• Low rate of tumor formation;
• high heterogeneity for site  
and type of tumor.
Mutant lines created 
by genome editing 
• Many mutant lines are available;
• good incidence of tumor formation;
• homogeneity of tumor types. 
• Mutant lines are difficult  
to maintain; 
• the study of tumors requires 
histological analysis. 
Transgenic zebrafish • Allows the expression of a gene of interest in 
a particular organ or tissue;
• a high rate of tumor formation;
• temporary and site control of tumor 
initiation. 
• If the cells are labeled, the possibility 
to monitor the tumor progression by 
fluorescence microscopy. 
• The necessity of high experience 
indeed transgenic lines could be 









i.e. the transplanted 
into zebrafish 
embryos of the 
patient-derived 
tumor cells (zPDX))  
• High penetrance;
• the number and location of tumor cells are 
controlled;
• rapid tumor progression;
• efficient and fast model to test the patient’s 
treatment options in an in vivo model having 
the same molecular, genetic, and clinical 
characteristics of the patient.
• Require embryos or immune 
system ablation through radiation 
or treatment with dexamethasone 
to avoid engraftment rejection;
• cells only survive for a few weeks 
or days;
• experimental temperature is not 
physiological for human cells;
• orthotopic transplantation is not 
always possible due to the absence 
of a concrete organ in zebrafish, 
such as for breast, lung, or 
prostate cancer.
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and used to complement experimental sys-
tems with the aim to add additional layers of 
complexity and to analyse challenging vari-
ables not easily studied experimentally. The 
literature evidences that a rigorous application 
of mathematical models is extremely valuable 
in preclinical development. For oncological 
drugs the key translational objectives concern 
the safety data and the scientific support for 
the rationale and biological plausibility of the 
investigational drug (90). Often the inadequa-
cy and the poor efficacy of the models used to 
investigate new anti-cancer drugs led to poor 
understanding of systemic drug toxicity and 
mechanism of action and then to the failure 
of the development program. Mathematical 
models can help the translation of both these 
key objectives of drug development. Regard-
ing the rationale and biological plausibility, the 
information on anti-tumour activity associated 
with an investigational drug, inferred from the 
xenograft model, can be used in mathematical 
models to define efficacy and predict clinical 
anti-tumour response. Regarding the tolerabil-
ity profile, some of the most common toxicities 
– myelosuppression, gastrointestinal toxicity 
and cardiac safety – can be readily described 
by mathematical models (91-94); in this con-
text the use of proper mathematical models 
may account for human tolerable exposures, 
thus rendering preclinical anti-tumour activity 
highly predictive of the overall response rate 
in the clinic. 
The compelling need to incorporate mathe-
matical models into the drug discovery pro-
cess at both preclinical and clinical stages is 
part of the transition in the process of drug 
discovery and development in oncology we 
are facing, and is determined by the grow-
ing knowledge of basic molecular and cellu-
lar mechanisms underlying carcinogenesis and 
immune-oncology as well as the availability 
of large amount of data (95, 96). For cytotox-
ic agents and most of the molecularly target-
ed antineoplastic agents, mathematical mod-
elling of the preclinical data can now predict 
the clinical efficacy and toxicity profile with 
good confidence. However, translation for im-
mune-oncology agents still remains very chal-
lenging (90, 97).
The growing use of mathematical modelling in 
oncology might provide a unifying framework 
for evaluating the potential of an investiga-
tional product. This could help determine the 
best clinical development strategy and will re-
sult in a rationale and more efficient drug de-
velopment process. The application of math-
ematical models in oncology drug discovery 
represents also an example of how efforts be-
tween different but potentially complementary 
disciplines can converge and work in synergy 
ensuring a more continuing translation of mod-
el and analysis techniques (90). Moreover, the 
integration and increasing application of the in 
silico approach during the drug discovery and 
development process also comply with eth-
ical requirements and the directives of Euro-
pean legislation on the use of animal models 
in experimentation since they well match the 
replacement, reduction and refinement of the 
3R principle (98, 99).
In future regards to precision medicine, math-
ematical models play an increasingly relevant 
and decisive role aiding the comprehension of 
complex systems in biomedical research, es-
pecially in the oncological field. This evolution 
towards the introduction of the computational 
analysis during the development of drugs, by 
combining in vitro, in vivo and in silico tech-
niques, allows refining experimental programs, 
providing more accurate and detailed models, 
ultimately resulting in higher specificity and 
speed. Overall, this has direct implications for 
both effective and individualized cancer thera-
pies ultimately achieving better patient survival.
CONCLUSIONS
There is a wide range of tumour models, each 
with distinct advantages and disadvantages. It 
is clear that any model is lacking some aspects 
of reality. While in vivo models can capture the 
complexity of the metastatic process in a living 
system, visualization of the individual steps is 
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challenging and extracting quantitative mech-
anistic data is usually very difficult. In contrast, 
in vitro models have reduced physiological rel-
evance, capturing only limited aspects of the 
TME, but allow control of most experimen-
tal variables and permit quantitative analysis 
(100). A further advancement has been intro-
duced with ex-vivo systems developed to im-
prove basic in vitro cell cultures while overcom-
ing shortcomings of preclinical animal models 
and serve as more clinically relevant models to 
predict drug response in cancer patients.
Looking at the appropriateness of the model 
and the translatability of the results, relevant 
data for efficacy and toxicity can be obtained 
if the preclinical model system integrates in vi-
tro, in vivo and in silico experiments. In fact, 
the complexity and heterogeneity of cancer, as 
well as the corresponding vast amount of avail-
able data, ask for a systemic approach such as 
computational modelling (95, 96) . Overall, in 
silico biological systems, especially integrated 
mathematical models, provide significant link 
and enrichment of in vitro and in vivo systems 
(figure 1). In addition, efforts to expand inte-
grative approaches to combine information on 
multiple levels – molecular, cellular, microen-
vironmental etc… - will further refine the ex-
perimental programs (101-103). Cancer and 
biomedical science in general will benefit from 
the combination of in silico with in vitro and 
in vivo methods resulting in higher specificity 
and speed, providing more accurate, detailed 
and refined models that ultimately support 
prediction and decision-making.
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